Reply to Letter: “Predictors of Contrast-Induced Nephropathy in Patients with ST-Elevation Myocardial Infarction”

Abstract

Get full access to this article

View all access options for this article.

References

Ozturk

Sener

. Predictors of contrast induced nephropathy in patients with STEMI. Angiology. 2024;75:397–397.

Saylik

Cınar

Akbulut

, et al. Serum Uric acid to albumin ratio can predict contrast-induced nephropathy in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. Angiology. 2024;75:398–399.

Lin

Dong

Liu

, et al. Renal safety and renin-angiotensin-aldosterone system inhibitors in patients with contrast media exposure: a multicenter randomized controlled study. J Cardiovasc Pharmacol. 2022;80:718–724.

Golshani

Tavasoli

Farsavian

, et al. Comparison of the incidence of contrast-induced nephropathy after primary PCI in patients receiving high-dose rosuvastatin and atorvastatin. J Family Med Prim Care. 2022;11:1957–1962.

Ibanez

James

Agewall

et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–177.

Karagkounis

. Cardiac and renal effects of sodium-glucose co- transporter 2 inhibitors. Drug Ther Bull. 2023;61:103–107.

Paolisso

Bergamaschi

Cesaro

, et al. Impact of SGLT2- inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: insight from SGLT2-I AMI PROTECT registry. Diabetes Res Clin Pract. 2023;202:110766.